An editorial reading of the tirzepatide safety record — what the 2024-2025 trials and pooled analyses actually measured about tolerability, signals, and risk.
Safe Tirzepatide

Tirzepatide Weight Loss: The Trial Evidence

The short version

Tirzepatide weight loss outcomes are the most impressive recorded in a randomised obesity drug trial. In SURMOUNT-1, the largest Phase 3 trial, participants without type 2 diabetes lost an average of 15.0% of body weight at the lowest studied maintenance dose (5 mg) and 20.9% at the highest (15 mg) over 72 weeks — compared with 3.1% in the placebo group. A 2025 head-to-head trial against semaglutide (a selective GLP-1 receptor agonist) found tirzepatide produced -20.2% mean weight change versus -13.7% with the comparator. A separate 2025 follow-up also found sustained tirzepatide weight loss reduced progression to type 2 diabetes in people with obesity. The mechanism involves dual GIP/GLP-1 receptor activation reducing appetite, slowing gastric emptying, and enhancing insulin signalling — the result is a caloric deficit that most participants sustain over the full trial duration.

Tirzepatide weight loss: what SURMOUNT-1 measured

SURMOUNT-1 (Jastreboff AM, et al.; NEJM 2022; NCT04184622) enrolled 2,539 adults with obesity (BMI ≥30, or ≥27 with a weight-related complication — such as hypertension, dyslipidaemia, or obstructive sleep apnea) and without type 2 diabetes. Participants received once-weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks; the 20-week dose-escalation phase preceded maintenance at the assigned dose. Mean percentage body-weight change at week 72 [4]:

  • 5 mg: -15.0%
  • 10 mg: -19.5%
  • 15 mg: -20.9%
  • Placebo: -3.1%

All three tirzepatide doses were significantly superior to placebo (P<0.001). Proportions reaching ≥5%, ≥10%, ≥15%, and ≥20% weight loss were significantly higher for all tirzepatide groups. The most common adverse events were gastrointestinal (predominantly nausea), most frequent during dose escalation, and mostly mild to moderate.

The weight-loss magnitude — approximately 21% mean loss at the maximum dose — was the largest ever reported in a randomised controlled obesity pharmacotherapy trial at the time of publication.

Tirzepatide weight loss: the 2025 head-to-head comparison (SURMOUNT-5)

SURMOUNT-5 (Aronne LJ, et al.; NEJM 2025; NCT05822752) was a phase 3b, open-label, randomised controlled trial in 751 adults with obesity (BMI ≥30, or ≥27 with a complication) but without type 2 diabetes. Participants received the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (a selective GLP-1 receptor agonist — 1.7 or 2.4 mg), once weekly for 72 weeks [5]. This is the only large randomised head-to-head weight-management comparison of the two drugs.

Least-squares mean weight change at week 72:

  • Tirzepatide: -20.2%
  • Semaglutide: -13.7%
  • Difference: -6.5 percentage points (P<0.001)

Tirzepatide also produced greater reductions in waist circumference and higher proportions of participants reaching each weight-loss threshold (10%, 15%, 20%, and 25%). The adverse event profile was consistent with the established safety record: gastrointestinal events were the most common in both groups.

The SURMOUNT-5 result provides the first head-to-head randomised evidence for tirzepatide's superiority over semaglutide in tirzepatide weight loss specifically in adults with obesity without diabetes.

Tirzepatide weight loss and diabetes prevention — 2025 follow-up

Jastreboff AM, et al. (NEJM 2025) reported the outcomes of a follow-up study examining whether tirzepatide-induced weight reduction reduced progression to type 2 diabetes in adults with obesity. The study found sustained weight reduction and reduced progression to type 2 diabetes in the tirzepatide group [36]. This extends the significance of tirzepatide weight loss beyond aesthetics or mobility to diabetes primary prevention — particularly relevant given that the drug is already approved for type 2 diabetes treatment.

Tirzepatide weight loss and concomitant weight-inducing medications: A 2026 post-hoc analysis of SURMOUNT-1, -3, and -4 (Galindo et al.) found that approximately 17–20% of participants across the trials were also taking medications that promote weight gain. Their percentage weight changes with tirzepatide (-13.3% at 5 mg to -21.3% at 15 mg in SURMOUNT-1; -26.1% at maximum tolerated dose in SURMOUNT-3; -18.6% at maximum tolerated dose in SURMOUNT-4) were comparable to the primary results not stratified by weight-inducing medication use [37]. This suggests the drug's efficacy is broadly maintained even when participants are also taking treatments that work against weight loss.

How does tirzepatide work for weight loss?

Tirzepatide achieves its weight-loss effect through dual incretin receptor activation — engaging both the GIP receptor and the GLP-1 receptor simultaneously. The downstream effects relevant to body-weight reduction are:

  1. Reduced appetite and food intake — GLP-1R activation in the hypothalamus and brainstem suppresses hunger signals; GIP receptor activation in fat and potentially in the brain also contributes to reduced energy intake.
  2. Delayed gastric emptying — food leaves the stomach more slowly, extending satiety and blunting post-meal glucose spikes.
  3. Enhanced glucose-dependent insulin secretion — dual receptor activation produces more insulin in response to elevated blood glucose, improving metabolic efficiency.
  4. Glucagon suppression — reduced pancreatic glucagon (the hormone that raises blood sugar) lowers hepatic glucose output.

The additive effect of GIP receptor activation on top of GLP-1 receptor activation appears to be the key to the larger weight losses observed versus selective GLP-1 receptor agonists, as the preclinical data (Coskun et al., 2018) and the head-to-head SURMOUNT-5 results both confirm [1][5]. Whether dual agonism produces strictly additive or synergistic effects, and the precise contribution of each receptor to the weight outcome, remain active areas of investigation.